Ventricular Arrhythmias in Seniors with Heart Failure: Present Dilemmas and Therapeutic Considerations: A Systematic Review

• Authors: Tuoyo O. Mene-Afejuku, Mayo Clinic; Abayomi O. Bamgboje, Metropolitan Hospital Center; Modele Ogunniyi, Emory University; Ola Akinboboye, Queens Heart Institute; Uzoma N. Ibebuogu, University of Tennessee
• Journal Title: Current Cardiology Reviews
• Volume: Volume 18, Number 2
• Publisher: Bentham Science Publishers | 2022-03-01, Pages 78-90
• Type of Work: Article | Final Publisher PDF
• Publisher DOI: http://doi.org/10.2174/1573403X17666211018095324
• Subjects: Health Sciences, Medicine and Surgery; Gerontology
• Keywords: Device therapy; heart failure; mortality; outcomes; seniors; ventricular arrhythmias; Arrhythmias, Cardiac; Cardiac Resynchronization Therapy; Defibrillators, Implantable; Heart Failure; Humans; Stroke Volume

Abstract

Background: Heart Failure (HF) is a global public health problem, which affects over 23 million people worldwide. The prevalence of HF is higher among seniors in the USA and other developed countries. Ventricular Arrhythmias (VAs) account for 50% of deaths among patients with HF. We aim to elucidate the factors associated with VAs among seniors with HF, as well as therapies that may improve the outcomes. Methods: PubMed, Web of Science, Scopus, Cochrane Library databases, Science Direct, and Google Scholar were searched using specific keywords. The reference lists of relevant articles were searched for additional studies related to HF and VAs among seniors as well as associated out-comes. Results: The prevalence of VAs increases with worsening HF. A 24-hour Holter electrocardiogram may be useful in risk stratifying patients for device therapy if they do not meet the criterion of low ventricular ejection fraction. Implantable Cardiac Defibrillators (ICDs) are superior to anti-arrhythmic drugs in reducing mortality in patients with HF. Guideline-Directed Medical Therapy (GDMT) together with device therapy may be required to reduce symptoms. In general, the proportion of seniors on GDMT is low. A combination of ICDs and cardiac resynchronization therapy may improve outcomes in selected patients. Conclusion: Seniors with HF and VAs have high mortality even with the use of device therapy and GDMT. The holistic effect of device therapy on outcomes among seniors with HF is equivocal. More studies focused on seniors with advanced HF as well as therapeutic options are, there-fore, required.